Trials
Registry mirror rows for research browsing. Trial exists does not mean clinical benefit. Filtered to rows matching "glioblastoma".
Open trial status does not mean eligibility or suitability. Review with oncology team.
Data: Live structured evidence (Supabase)
Open or active trials (125)
Open identifiers on the public registry for primary protocol text.
| NCT ID | Title | Status | Phase | Conditions | Interventions | Countries | Last updated | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | RECRUITING | PHASE2, PHASE3 | Glioblastoma | Temozolomide, Lomustine, Regorafenib, Radiation +7 | Australia, Canada, France, Germany +2 | 2026-05-15 | CT.gov |
| NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors | NOT_YET_RECRUITING | NA | Brain Injuries, Acute, Brain Tumor Adult, Brain (Nervous System) Cancers, Traumatic Brain Injuries +3 | Supportive Care | Denmark | 2026-05-15 | CT.gov |
| NCT07485049 | BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors | RECRUITING | EARLY_PHASE1 | Glioblastoma (GBM) | BGB-58067 | United States | 2026-05-14 | CT.gov |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | ACTIVE_NOT_RECRUITING | PHASE1 | Recurrent Glioblastoma, Refractory Glioblastoma | IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab, Quality-of-Life Assessment +1 | United States | 2026-05-14 | CT.gov |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | RECRUITING | PHASE1 | Glioblastoma | CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination | United States | 2026-05-11 | CT.gov |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | ACTIVE_NOT_RECRUITING | PHASE1 | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +3 | Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat | United States | 2026-05-07 | CT.gov |
| NCT03115333 | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma | ACTIVE_NOT_RECRUITING | NA | Gliosarcoma, Recurrent Glioblastoma | Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging | United States | 2026-05-06 | CT.gov |
| NCT05708352 | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | RECRUITING | PHASE2 | Glioblastoma Multiforme | Keto Diet, Standard Anti-Cancer Diet | United States | 2026-05-06 | CT.gov |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE1 | Glioblastoma | B7-H3-targeting CAR-T cells | China | 2026-05-04 | CT.gov |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | RECRUITING | PHASE3 | Glioblastoma | Optune® device, Temozolomide, Pembrolizumab, Placebo | Canada, Czechia, France, Germany +8 | 2026-05-01 | CT.gov |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | RECRUITING | PHASE1, PHASE2 | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III | Debio 0123, Temozolomide, Radiotherapy | Spain, Switzerland, United States | 2026-04-28 | CT.gov |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM | RECRUITING | PHASE1 | Recurrent Glioblastoma, Glioblastoma Multiforme, GBM | 5-ALA and Low-Intensity Focused Ultrasound (SDT) | United States | 2026-04-28 | CT.gov |
| NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | RECRUITING | NA | Malignant Solid Brain Tumors, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Brain Metastasis +1 | Autologous NK cells | China | 2026-04-27 | CT.gov |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | RECRUITING | - | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma +4 | Specific PET imaging agents targeting LRRC15 | China | 2026-04-27 | CT.gov |
| NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | RECRUITING | PHASE1 | Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas +1 | Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery, Fludarabine | China | 2026-04-24 | CT.gov |
| NCT03383978 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma | RECRUITING | PHASE1 | Glioblastoma | NK-92/5.28.z, Ezabenlimab | Germany | 2026-04-23 | CT.gov |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | RECRUITING | PHASE2 | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma +6 | Ribociclib, Everolimus, Temozolomide (TMZ) | Australia, Canada, Germany, Netherlands +3 | 2026-04-22 | CT.gov |
| NCT06069726 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | RECRUITING | PHASE2 | Recurrent Glioblastoma | Atezolizumab | United States | 2026-04-21 | CT.gov |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | ACTIVE_NOT_RECRUITING | EARLY_PHASE1 | Glioblastoma | Zimberelimab, Domvanalimab, Placebo | United States | 2026-04-17 | CT.gov |
| NCT02800486 | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | RECRUITING | PHASE2 | Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma +5 | Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation | United States | 2026-04-13 | CT.gov |
| NCT07089641 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | RECRUITING | PHASE1 | IDH Wildtype Glioblastoma, Recurrent Astrocytoma, IDH Wildtype Recurrent Glioblastoma, Resectable Astrocytoma +1 | Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18 +3 | United States | 2026-04-07 | CT.gov |
| NCT05474378 | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | RECRUITING | PHASE1 | Brain and Nervous System | B7-H3CART | United States | 2026-04-07 | CT.gov |
| NCT06850766 | The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma | RECRUITING | NA | IDH-Wildtype Glioblastoma, Glioblastoma (GBM) | Morning administration of TMZ, Evening administration of TMZ | Canada | 2026-04-02 | CT.gov |
| NCT05839379 | Targeted Pediatric High-Grade Glioma Therapy | RECRUITING | - | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma +5 | - | Australia, Canada, Germany, Netherlands +3 | 2026-03-31 | CT.gov |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme, Astrocytoma, Grade III | ADV/HSV-tk (gene therapy) | United States | 2026-03-30 | CT.gov |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures | RECRUITING | NA | Brain Tumor Adult, Brain Tumor Benign, Meningioma, Glioma +1 | Absorbable running intradermal suture, Non-absorbable interrupted transdermal suture | Poland | 2026-03-27 | CT.gov |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | NOT_YET_RECRUITING | EARLY_PHASE1 | Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer +1 | Panitumumab-IRDye800 | - | 2026-03-25 | CT.gov |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme | ACP-196 | United States | 2026-03-25 | CT.gov |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | RECRUITING | PHASE1 | Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer +2 | RSC-1255 Dose Escalation, RSC-1255 Dose Expansion | United States | 2026-03-18 | CT.gov |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | RECRUITING | EARLY_PHASE1 | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma +5 | Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation | Australia, Canada, Germany, Netherlands +2 | 2026-03-12 | CT.gov |
| NCT07457307 | Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac | NOT_YET_RECRUITING | PHASE1 | High-grade Glioma | MR-Linac System, Radiation Therapy, Temozolomide | United States | 2026-03-09 | CT.gov |
| NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases | RECRUITING | EARLY_PHASE1 | Glioblastoma (GBM), Brain Metastasases | Risvutatug rezetecan | United States | 2026-03-06 | CT.gov |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | ACTIVE_NOT_RECRUITING | PHASE1 | Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges | IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes | United States | 2026-03-05 | CT.gov |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | ACTIVE_NOT_RECRUITING | PHASE1 | Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma +10 | rQNestin, Cyclophosphamide, Stereotactic biopsy | United States | 2026-03-04 | CT.gov |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | RECRUITING | PHASE1, PHASE2 | Glioblastoma | Ivonescimab | United States | 2026-02-27 | CT.gov |
| NCT07420543 | Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach | RECRUITING | - | Brain Tumors and/or Solid Tumors Including, Glioblastoma, Glioblastoma (GBM), Glioblastoma - Category | - | Italy | 2026-02-19 | CT.gov |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors | RECRUITING | - | Brain Tumor Adult, Brain Tumor Benign, CerebroSpinal Fluid (CSF) Leak, Craniotomy +3 | - | Poland | 2026-02-17 | CT.gov |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial | RECRUITING | PHASE2 | Glioblastoma, Recurrence Tumor | Trimipramine, Cohort 1: Atezolizumab, Bevacizumab, Cohort 2: Atezolizumab +1 | Switzerland | 2026-02-13 | CT.gov |
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | NOT_YET_RECRUITING | EARLY_PHASE1 | Glioblastoma, GBM | Acetadote | United States | 2026-02-06 | CT.gov |
| NCT03405792 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma, Glioblastoma, WHO Grade IV | Temozolomide (TMZ), Optune System, Pembrolizumab | United States | 2026-02-06 | CT.gov |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | NOT_YET_RECRUITING | PHASE1, PHASE2 | Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant +1 | ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) | United States | 2026-02-05 | CT.gov |
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | Glioblastoma | Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg | Spain | 2026-02-05 | CT.gov |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | RECRUITING | - | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma | Specimen Collection | United States | 2026-02-04 | CT.gov |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma | RECRUITING | PHASE2 | Glioblastoma Multiforme, Adult | Integrated boost technique (SIB) guided by PET FDOPA | France | 2026-02-04 | CT.gov |
| NCT03251027 | Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma | ACTIVE_NOT_RECRUITING | NA | Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma | Intensity-Modulated Radiation Therapy, Quality-of-Life | United States | 2026-01-27 | CT.gov |
| NCT07365280 | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma | NOT_YET_RECRUITING | PHASE2 | Glioblastoma | Personalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ) | - | 2026-01-26 | CT.gov |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | RECRUITING | PHASE1 | Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma | Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection | United States | 2026-01-23 | CT.gov |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas | Avutometinib, Defactinib, Temozolomide | United Kingdom | 2026-01-21 | CT.gov |
| NCT04479696 | Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors | RECRUITING | NA | Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma | Educational Intervention, Questionnaire Administration, Survey Administration, Video | United States | 2026-01-20 | CT.gov |
| NCT02179086 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma | 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis +5 | Canada, United States | 2026-01-14 | CT.gov |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | RECRUITING | PHASE1 | Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor | Indoximod, Ibrutinib, Cyclophosphamide, Etoposide +2 | United States | 2026-01-09 | CT.gov |
| NCT04221503 | Niraparib/TTFields in GBM | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma, Recurrent Glioblastoma, GBM | Niraparib, Optune, Planned surgical resection | United States | 2026-01-08 | CT.gov |
| NCT06558214 | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial | RECRUITING | PHASE2 | Recurrent Glioblastoma | Pembrolizumab, Optune GIO®, NeuroBlate® | United States | 2026-01-07 | CT.gov |
| NCT04959500 | Newly Diagnosed Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma | Anlotinib Hydrochloride, Placebo, Radiation Therapy, Temozolomide | China | 2026-01-02 | CT.gov |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | RECRUITING | PHASE1, PHASE2 | Glioblastoma | VRT106 | China | 2026-01-02 | CT.gov |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | RECRUITING | PHASE2 | Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, STAT3 Inhibitor WP1066 +1 | United States | 2025-12-30 | CT.gov |
| NCT02177578 | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma Multiforme | Temozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiation | United States | 2025-12-18 | CT.gov |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | RECRUITING | PHASE1 | Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor +5 | Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) | United States | 2025-12-16 | CT.gov |
| NCT07284628 | Vortioxetine for Newly Diagnosed Glioblastoma | NOT_YET_RECRUITING | PHASE2 | Glioblastoma | Vortioxetine | - | 2025-12-16 | CT.gov |
| NCT02344355 | A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma Multiforme | Temozolomide, radiation therapy, Ascorbic Acid | United States | 2025-12-12 | CT.gov |
| NCT07274397 | Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma | NOT_YET_RECRUITING | NA | Glioblastoma, Brain Tumors, Brain Imaging | Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium | - | 2025-12-10 | CT.gov |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma +4 | SIACI of cetuximab and bevacizumab | United States | 2025-12-08 | CT.gov |
| NCT06613841 | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma | RECRUITING | EARLY_PHASE1 | Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain | Fluciclovine F18 | United States | 2025-11-28 | CT.gov |
| NCT04945148 | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide | RECRUITING | PHASE2 | Glioblastoma, IDH-wildtype | Metformin, Radiation IMRT, Temozolomide | France, Italy | 2025-11-21 | CT.gov |
| NCT06072586 | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions | RECRUITING | EARLY_PHASE1 | High Grade Glioma, Glioblastoma | BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy | United States | 2025-11-20 | CT.gov |
| NCT07211841 | Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM) | NOT_YET_RECRUITING | NA | Glioblastoma, MRI Spectroscopy, Tumor Microenvironment, Biomarkers / Blood | MRS study, blood samples | France | 2025-11-19 | CT.gov |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | RECRUITING | EARLY_PHASE1 | Glioblastoma | Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT | United States | 2025-11-12 | CT.gov |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | RECRUITING | PHASE2 | Glioblastoma | Temozolomide, Neratinib, QBS10072S, Abemaciclib +1 | United States | 2025-11-10 | CT.gov |
| NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | PHASE3 | Glioblastoma | Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide | Brazil, Canada, China, Germany +4 | 2025-10-14 | CT.gov |
| NCT07145112 | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | RECRUITING | PHASE1 | Glioblastoma | Laser interstitial thermal therapy, Lomustine | United States | 2025-10-09 | CT.gov |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor | pH Measurement of in vivo tissue | United States | 2025-10-08 | CT.gov |
| NCT04214392 | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE1 | Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma | Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery) | United States | 2025-10-06 | CT.gov |
| NCT06835803 | Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial | RECRUITING | PHASE2 | Glioblastoma (GBM) | Dose-escalated radiation therapy, Standard hypofractionated radiation | United States | 2025-09-18 | CT.gov |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow | NOT_YET_RECRUITING | PHASE2 | Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial Intelligence | Adaptive radiotherapy | - | 2025-09-16 | CT.gov |
| NCT07141732 | Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy | RECRUITING | PHASE1 | Glioblastoma | Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System | Russia | 2025-09-16 | CT.gov |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | ACTIVE_NOT_RECRUITING | EARLY_PHASE1 | High Grade Glioma, Glioblastoma Multiforme | DSP-0390 | Japan, United States | 2025-09-16 | CT.gov |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity | RECRUITING | NA | Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3 +3 | Blood samples, tumor biopsy specimens and ascites samples will be collected. | France | 2025-09-15 | CT.gov |
| NCT05120284 | Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma Multiforme | Dichloroacetate (DCA), Genotype | United States | 2025-08-29 | CT.gov |
| NCT04863950 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | RECRUITING | PHASE2 | Glioblastoma | Lomustine, Imipramine Hydrochloride | United States | 2025-08-27 | CT.gov |
| NCT04188535 | Serial MRI Scans During Radiation Therapy | RECRUITING | NA | Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging +4 | MRI IMAGING | United States | 2025-08-26 | CT.gov |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | NOT_YET_RECRUITING | PHASE2 | Recurrent Glioblastoma | KH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16 | - | 2025-08-22 | CT.gov |
| NCT06177964 | Lerapolturev (PVSRIPO) in GBM | RECRUITING | PHASE2 | Recurrent Supratentorial Glioblastoma | Lerapolturev, Lomustine Pill | United States | 2025-08-17 | CT.gov |
| NCT02974621 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE2 | Recurrent Glioblastoma | Bevacizumab, Cediranib, Cediranib Maleate, Olaparib | United States | 2025-08-03 | CT.gov |
| NCT05284643 | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | RECRUITING | NA | Recurrent Glioblastoma | Intensity Modulated Proton Therapy (IMPT), Bevacizumab | United States | 2025-08-01 | CT.gov |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | RECRUITING | EARLY_PHASE1 | Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma +4 | Microdevice | United States | 2025-07-23 | CT.gov |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases | RECRUITING | PHASE2 | Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma | Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] | Israel | 2025-07-22 | CT.gov |
| NCT07052877 | The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab | NOT_YET_RECRUITING | - | Glioblastoma, Glioblastoma Multiforme (GBM) | PSMA PET/CT scan | Australia | 2025-07-11 | CT.gov |
| NCT04780009 | Loupe-Based Intraoperative Fluorescence Imaging | RECRUITING | - | Glioblastoma Multiforme, Anaplastic Astrocytoma | - | United States | 2025-07-09 | CT.gov |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | RECRUITING | PHASE1 | Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM) +1 | BC008-1A, BC008-1A | China | 2025-07-09 | CT.gov |
| NCT06954636 | Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study | RECRUITING | - | Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma, Glioblastoma, Adult | olfactory testing (threshold and identification test) | Germany | 2025-07-08 | CT.gov |
| NCT04047706 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE1 | Glioblastoma | IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide +2 | United States | 2025-06-29 | CT.gov |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | RECRUITING | PHASE2 | Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer +14 | APL-101 Oral Capsules | Australia, Canada, France, Hungary +7 | 2025-06-27 | CT.gov |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | RECRUITING | PHASE1 | Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype +3 | Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide | United States | 2025-06-25 | CT.gov |
| NCT06883747 | Clinical Trial of BMS-986504 in Recurrent GBM Patients | RECRUITING | EARLY_PHASE1 | Glioblastoma WHO Grade IV | BMS-986504 | United States | 2025-06-19 | CT.gov |
| NCT03477513 | Personalized Radiation Therapy for GBM | ACTIVE_NOT_RECRUITING | NA | Glioblastoma | Radation Therapy | United States | 2025-06-18 | CT.gov |
| NCT05775458 | Glutamate Excitotoxicity and Its Role in Glioblastoma Biology | RECRUITING | - | Brain Tumor, Primary | Blood, CSF and tumor samples | Italy | 2025-06-11 | CT.gov |
| NCT06551909 | Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2) | RECRUITING | NA | Glioblastoma | Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost | Italy | 2025-06-08 | CT.gov |
| NCT06264388 | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | RECRUITING | PHASE2 | High Grade Glioma, Anaplastic Astrocytoma | DB107-RRV, DB107-FC | United States | 2025-05-29 | CT.gov |
| NCT03897491 | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma | 5-aminolevulinic acid | Germany | 2025-05-14 | CT.gov |
| NCT06939400 | Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence | NOT_YET_RECRUITING | - | Glioblastoma Multiforme (GBM) | Photodynamic therapy (PDT), GBM patients recevied traditional treatment options | China | 2025-04-22 | CT.gov |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma | Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td +1 | United States | 2025-04-15 | CT.gov |
| NCT03452579 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | ACTIVE_NOT_RECRUITING | PHASE2 | Glioblastoma | Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab | United States | 2025-02-28 | CT.gov |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | RECRUITING | PHASE1, PHASE2 | Glioblastoma, Recurrent Glioblastoma | Verteporfin | United States | 2025-02-25 | CT.gov |
| NCT06845020 | CSF Proteomic Characterization of Glioblastomas | NOT_YET_RECRUITING | - | Glioblastoma, Glioblastoma WHO Grade IV, Glioblastoma (GBM), Glioblastoma Multiforme of the Brain +1 | - | - | 2025-02-25 | CT.gov |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy | RECRUITING | - | Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma +2 | Functional drug screen | United Kingdom | 2025-02-24 | CT.gov |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema | RECRUITING | PHASE2 | Glioblastoma, Cerebral Metastases, Meningioma | Salovum/SPC flakes | Sweden | 2025-01-27 | CT.gov |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma | RECRUITING | PHASE1 | Recurrent Glioblastoma | Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV, Neurosurgery and intracavitary injection nivolumab and ipililumab, Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary | Belgium | 2025-01-20 | CT.gov |
| NCT05590689 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor | RECRUITING | PHASE1, PHASE2 | Glioblastoma | Gliolan, Radiodynamic therapy | Germany | 2024-12-16 | CT.gov |
| NCT06691308 | WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients | NOT_YET_RECRUITING | EARLY_PHASE1 | Recurrent or Progressive Glioblastoma | WL276 CAR-T cells | - | 2024-11-18 | CT.gov |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | Glioblastoma | Hypofractionated radiotherapy, Temozolomide | United States | 2024-10-31 | CT.gov |
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | ENROLLING_BY_INVITATION | PHASE1 | Recurrent Glioblastoma Multiforme (GBM) | SNC109 | China | 2024-09-27 | CT.gov |
| NCT03630289 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | ACTIVE_NOT_RECRUITING | NA | Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer | Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) | United States | 2024-09-19 | CT.gov |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | Glioblastoma Multiforme of Brain | Dendritic cell vaccine plus temozolomide chemotherapy | Belgium | 2024-09-19 | CT.gov |
| NCT05271240 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | RECRUITING | PHASE3 | Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM +3 | Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone | United States | 2024-09-19 | CT.gov |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | NOT_YET_RECRUITING | PHASE1 | Glioblastoma | Survivin-loaded dendritic cell injection | - | 2024-07-29 | CT.gov |
| NCT05990556 | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | RECRUITING | NA | Glioblastoma, Meningeal Arteries | interventional procedure to block bilateral meningeal blood supply | China | 2024-07-24 | CT.gov |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma | RECRUITING | PHASE1 | Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Radiotherapy; Complications +1 | hypofractionated stereotactic radiotherapy, Stereotactic biopsy, resection, Chemotherapy +2 | Spain | 2024-05-16 | CT.gov |
| NCT05768087 | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | RECRUITING | NA | Glioblastoma | Escalated proton therapy | Denmark | 2024-05-09 | CT.gov |
| NCT06283927 | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) | RECRUITING | - | Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain +4 | Re-resection, Temozolomide, Lomustine, Re-irradiation +2 | Belgium, Germany, Netherlands, Switzerland +1 | 2024-02-28 | CT.gov |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis | RECRUITING | - | Pancreas Adenocarcinoma, Small-cell Lung Cancer, Glioblastoma, IDH-wildtype | Long term survival multimodal analysis | France | 2023-12-07 | CT.gov |
| NCT06146725 | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) | RECRUITING | - | Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult +1 | Tumor resection, Tumor biopsy | Belgium, Germany, Netherlands, Switzerland +1 | 2023-11-27 | CT.gov |
| NCT06146738 | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) | RECRUITING | - | Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult | Palliative Care, Tumor biopsy, Tumor resection | Belgium, Germany, Netherlands, Switzerland +1 | 2023-11-27 | CT.gov |
| NCT05917821 | New Antigens Against Glioblastoma | NOT_YET_RECRUITING | - | Glioblastoma Multiforme | - | - | 2023-07-24 | CT.gov |
| NCT05541042 | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | NOT_YET_RECRUITING | - | Glioblastoma | Observational only | China | 2022-09-27 | CT.gov |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | NOT_YET_RECRUITING | PHASE2 | Glioblastoma | Tislelizumab plus Bevacizumab | China | 2022-09-27 | CT.gov |
Completed trials with indexed results (104)
Open identifiers on the public registry for primary protocol text.
| NCT ID | Title | Status | Phase | Conditions | Interventions | Countries | Last updated | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06796335 | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour | COMPLETED | - | Brain Injury, Brain Tumor Adult, Traumatic Brain Injury, Glioblastoma | RIGht | Denmark | 2026-05-07 | CT.gov |
| NCT06625047 | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy | COMPLETED | PHASE4 | Astrocytoma, IDH-Mutant, Glioblastoma, Glioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted | Assessment, Questionnaire Administration, Telemedicine Visit, Temozolomide | United States | 2026-04-29 | CT.gov |
| NCT02631655 | POSitron Emission Imaging Using 18F-FDOPA in Neurooncology | COMPLETED | NA | Glioblastoma | impact of device 18F-FDOPA PET on treatment decisions | France | 2026-04-23 | CT.gov |
| NCT02286167 | Glioma Modified Atkins-based Diet in Patients With Glioblastoma | COMPLETED | NA | Glioblastoma Multiforme | Diet modification | United States | 2026-03-24 | CT.gov |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | COMPLETED | PHASE1 | Glioblastoma | Capecitabine, Bevacizumab | United States | 2026-02-23 | CT.gov |
| NCT03048240 | INtraoperative photoDYnamic Therapy of GliOblastoma | COMPLETED | NA | Glioblastoma | "perPDT", GLIOLAN | France | 2026-02-05 | CT.gov |
| NCT01582269 | A Study in Recurrent Glioblastoma (GB) | COMPLETED | PHASE2 | Glioblastoma | Galunisertib, Lomustine, Placebo | Australia, Belgium, Canada, France +6 | 2025-11-24 | CT.gov |
| NCT03975959 | Memory Perception Assessment in Central/Non-central Nervous System Cancers | COMPLETED | NA | Glioblastoma, Glioma, Breast Cancer, Healthy | QMRP questionnaire | France | 2025-09-23 | CT.gov |
| NCT03050736 | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | COMPLETED | PHASE2 | Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1 | VAL-083 (Dianhydrogalactitol) | China | 2025-09-04 | CT.gov |
| NCT03344250 | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | COMPLETED | PHASE1 | Glioblastoma, Glioblastoma Multiforme | EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ | United States | 2025-03-06 | CT.gov |
| NCT03150862 | A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma | COMPLETED | PHASE1, PHASE2 | Brain and Central Nervous System Tumors | Pamiparib, TMZ, Radiation | Australia, France, Netherlands, Switzerland +1 | 2025-02-04 | CT.gov |
| NCT02465268 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV +1 | pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline +1 | United States | 2025-01-14 | CT.gov |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Recurrent Glioblastoma Multiforme | Stereotactic hypofractionated RT 5x5Gy, Stereotactic hypofractionated RT 5x7Gy | Brazil | 2024-12-09 | CT.gov |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | COMPLETED | PHASE1, PHASE2 | Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma +8 | Mebendazole, Vincristine, Carboplatin, Temozolomide +2 | United States | 2024-07-05 | CT.gov |
| NCT02490800 | Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma | COMPLETED | PHASE1, PHASE2 | Neoplasms | Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion | Belgium, Germany, Switzerland, United Kingdom | 2024-06-26 | CT.gov |
| NCT04143425 | Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | COMPLETED | - | Adult Glioblastoma, Magnetic Resonance Imaging, Bevacizimab | 3-Tesla conventional magnetic resonance imaging, Advanced imaging without contrast use, Dynamic susceptibility contrast-weighted imaging | South Korea | 2024-05-14 | CT.gov |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | COMPLETED | PHASE1 | Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant +2 | Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy | Canada, United States | 2024-01-31 | CT.gov |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | COMPLETED | PHASE1 | Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma +2 | CC-122, CC-122, CC-122, CC-122 | Belgium, France, Italy, Spain +1 | 2023-12-12 | CT.gov |
| NCT03463265 | Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | COMPLETED | PHASE2 | High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine +2 | United States | 2023-11-07 | CT.gov |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | COMPLETED | PHASE1 | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma | AdV-tk, Valacyclovir | United States | 2023-08-25 | CT.gov |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | COMPLETED | PHASE1 | Glioblastoma Multiforme | AZD2014 | Canada | 2023-08-04 | CT.gov |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | COMPLETED | PHASE1, PHASE2 | Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma +2 | Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery | United States | 2023-06-18 | CT.gov |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM | COMPLETED | PHASE2 | Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme | Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs +3 | United States | 2023-06-08 | CT.gov |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | COMPLETED | PHASE1, PHASE2 | Glioma, High Grade Astrocytoma, Glioblastoma Multiforme | Cancer vaccine plus immune adjuvant | United States | 2023-06-01 | CT.gov |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification | COMPLETED | PHASE3 | Glioblastoma, Gliosarcoma | Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414 | Argentina, Australia, Austria, Belgium +24 | 2023-05-11 | CT.gov |
| NCT02617589 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | COMPLETED | PHASE3 | Brain Cancer | Nivolumab, Temozolomide, Radiotherapy | Australia, Austria, Belgium, Canada +15 | 2023-03-28 | CT.gov |
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | COMPLETED | PHASE1 | Gliosarcoma, Supratentorial Glioblastoma | Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Temozolomide | United States | 2023-01-10 | CT.gov |
| NCT01865162 | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study | COMPLETED | PHASE1 | Glioblastoma Multiforme | ketogenic diet | United States | 2022-11-09 | CT.gov |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | COMPLETED | EARLY_PHASE1 | Gliosarcoma, Recurrent Glioblastoma | Laboratory Biomarker Analysis, Pharmacological Study, Targeted Molecular Therapy | United States | 2022-08-26 | CT.gov |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | COMPLETED | PHASE2 | MGMT-unmethylated Glioblastoma (GBM), GBM | Nivolumab, Ipilimumab, Radiation Therapy (RT) | United States | 2022-07-01 | CT.gov |
| NCT02968940 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | Avelumab, Hypofractionated radiation therapy (HFRT) | United States | 2022-06-29 | CT.gov |
| NCT01062399 | Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1, PHASE2 | Brain and Central Nervous System Tumors | concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day +3 | Canada, Israel, United States | 2022-06-09 | CT.gov |
| NCT02379572 | Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas | COMPLETED | NA | Glioblastoma | iMRI-guided surgery, 5-ALA-guided surgery | Germany | 2021-10-22 | CT.gov |
| NCT03034135 | Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma | COMPLETED | PHASE2 | Recurrent Glioblastoma | Disulfiram/Copper, Temozolomide (TMZ) | United States | 2021-09-13 | CT.gov |
| NCT01851733 | MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme | COMPLETED | PHASE1 | Glioblastoma | MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging | United States | 2021-08-27 | CT.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | COMPLETED | PHASE1, PHASE2 | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer +12 | Sacituzumab Govitecan-hziy (SG) | United States | 2021-08-12 | CT.gov |
| NCT01120639 | Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform | COMPLETED | PHASE1, PHASE2 | Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme | Temozolomide, Stereotactic Radiosurgery (SRS) | United States | 2021-08-06 | CT.gov |
| NCT00590681 | Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Glioblastoma Multiforme | Bevacizumab and Temozolomide | United States | 2021-03-30 | CT.gov |
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | COMPLETED | PHASE2, PHASE3 | Glioma, Glioblastoma | Disulfiram, Copper, Alkylating Agents | Norway, Sweden | 2021-03-18 | CT.gov |
| NCT00626483 | Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia | COMPLETED | PHASE1 | Malignant Neoplasms Brain | RNA-loaded dendritic cell vaccine, basiliximab | United States | 2021-03-09 | CT.gov |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas | COMPLETED | PHASE1 | Glioblastoma | C225-ILs-dox | Switzerland | 2020-12-08 | CT.gov |
| NCT01013285 | Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | bevacizumab, temozolomide, external beam radiation therapy | United States | 2020-09-21 | CT.gov |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | COMPLETED | PHASE1, PHASE2 | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma | enzastaurin, temozolomide, radiation therapy | United States | 2020-08-06 | CT.gov |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | COMPLETED | PHASE1, PHASE2 | Patients With Newly Diagnosed Glioblastoma | PLX3397, Radiation Therapy, Temozolomide | United States | 2020-06-30 | CT.gov |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | COMPLETED | PHASE1 | Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor +4 | Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide +1 | United States | 2020-06-04 | CT.gov |
| NCT02431572 | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | COMPLETED | NA | Intracranial Tumors, Glioblastoma, Melanoma | PBR PET, Cancer Immunotherapy, Radiation and chemotherapy | United States | 2020-04-28 | CT.gov |
| NCT01989884 | An Efficacy Study Of Ortataxel In Recurrent Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | Ortataxel | Italy | 2019-10-23 | CT.gov |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | COMPLETED | PHASE1, PHASE2 | Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma +9 | 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study +2 | United States | 2019-08-13 | CT.gov |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | COMPLETED | PHASE3 | Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma | 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis +3 | Canada, Israel, United States | 2019-07-24 | CT.gov |
| NCT03626896 | Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients | COMPLETED | NA | Glioblastoma Multiforme, Brain Tumor, Glioblastoma, Glioma +2 | NaviFUS System | Taiwan | 2019-06-21 | CT.gov |
| NCT01478854 | Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide | COMPLETED | NA | Glioblastoma Multiforme | Radiation, Chemotherapy | United States | 2019-06-13 | CT.gov |
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | COMPLETED | PHASE1 | Glioblastoma Multiforme (GBM) | HER.CAR CMV-specific CTLs | United States | 2019-04-25 | CT.gov |
| NCT03660761 | Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | COMPLETED | PHASE2 | Efficacy and Safety | apatinib, temodar | China | 2019-04-16 | CT.gov |
| NCT00093964 | Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) | COMPLETED | PHASE2 | Glioblastoma Multiforme | Cilengitide 500 mg, Cilengitide 2000 mg | United States | 2019-04-16 | CT.gov |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | Tivozanib | United States | 2019-01-08 | CT.gov |
| NCT00720356 | Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | bevacizumab, erlotinib hydrochloride | United States | 2018-10-26 | CT.gov |
| NCT02253212 | Safety of BBB Opening With the SonoCloud | COMPLETED | PHASE1, PHASE2 | Glioblastoma, Glioma, Brain Tumor | SonoCloud, Carboplatin | France | 2018-10-12 | CT.gov |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | COMPLETED | PHASE2 | Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm | Bevacizumab, Irinotecan Hydrochloride, Temozolomide | United States | 2018-09-17 | CT.gov |
| NCT02666066 | Radiomics for Prediction of Survival in GBM | COMPLETED | - | Glioblastoma, Glioma, Astrocytoma | - | Netherlands | 2018-08-17 | CT.gov |
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | COMPLETED | PHASE2 | Glioblastoma | Bevacizumab, Nimustine | China | 2018-07-31 | CT.gov |
| NCT01907165 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | COMPLETED | EARLY_PHASE1 | Glioblastoma | Temozolomide, Disulfiram, Copper gluconate | United States | 2018-07-20 | CT.gov |
| NCT00006358 | Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | temozolomide, thalidomide | United States | 2018-06-26 | CT.gov |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | COMPLETED | PHASE1 | Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma | Toca 511, Toca FC | United States | 2018-05-21 | CT.gov |
| NCT00974987 | Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment), TMZ(temozolomide) | Japan | 2018-04-25 | CT.gov |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | COMPLETED | PHASE2 | Glioblastoma Multiforme of the Brain | Antineoplaston therapy (Atengenal + Astugenal) | United States | 2018-03-22 | CT.gov |
| NCT01342757 | Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | COMPLETED | NA | Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor | vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration | United States | 2018-01-29 | CT.gov |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Adult Glioblastoma Multiforme | olaratumab, ramucirumab | United States | 2017-12-27 | CT.gov |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | COMPLETED | PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | dovitinib, laboratory biomarker analysis | United States | 2017-12-12 | CT.gov |
| NCT01800695 | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | COMPLETED | PHASE1 | Glioblastoma Multiforme | ABT-414, Temozolomide, Whole Brain Radiation | - | 2017-11-21 | CT.gov |
| NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma | COMPLETED | PHASE1 | Glioblastoma Multiforme, Recurrent Tumor | DNX2401 and Temozolomide | Spain | 2017-10-24 | CT.gov |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | COMPLETED | PHASE1, PHASE2 | Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | ixabepilone, pharmacological study, Anticonvulsant | United States | 2017-10-18 | CT.gov |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | COMPLETED | PHASE2 | Glioma | BIBW 2992, TMZ, BIBW 2992 plus TMZ | Canada, United States | 2017-08-15 | CT.gov |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | COMPLETED | PHASE2 | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +2 | Bendamustine Hydrochloride, Quality-of-Life Assessment | United States | 2017-07-07 | CT.gov |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) | COMPLETED | PHASE2 | Glioblastoma | bevacizumab, irinotecan | - | 2017-05-16 | CT.gov |
| NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | COMPLETED | PHASE3 | Glioblastoma Multiforme | NovoTTF-100A device, Temozolomide | Austria, Canada, Czechia, France +8 | 2017-04-10 | CT.gov |
| NCT00643097 | Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Malignant Neoplasms of Brain | PEP-3 vaccine, sargramostim, Temozolomide | United States | 2017-02-01 | CT.gov |
| NCT00813943 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status | COMPLETED | PHASE2 | Glioblastoma | Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy | Germany, United States | 2017-01-30 | CT.gov |
| NCT00003996 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | carmustine, chemotherapy, cisplatin, etoposide +1 | United States | 2016-12-07 | CT.gov |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | COMPLETED | PHASE1, PHASE2 | Glioblastoma Multiforme | Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy) | Germany | 2016-10-17 | CT.gov |
| NCT01474239 | A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma | COMPLETED | PHASE2 | Glioblastoma Multiforme | bevacizumab [Avastin], fotemustine | Italy | 2016-03-15 | CT.gov |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | COMPLETED | PHASE2 | Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +4 | sunitinib malate, pharmacological study | United States | 2016-02-29 | CT.gov |
| NCT00498927 | Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis +1 | United States | 2016-02-29 | CT.gov |
| NCT00704808 | Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) | COMPLETED | - | Glioblastoma | Primary surgical treatment, Radiotherapy, Temozolomide | - | 2015-09-09 | CT.gov |
| NCT00004146 | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | COMPLETED | PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | radiation therapy, carboxyamidotriazole, pharmacological study | United States | 2015-05-08 | CT.gov |
| NCT00821080 | Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | COMPLETED | PHASE1 | Glioblastoma | Sirolimus, Vandetanib | United States | 2015-05-01 | CT.gov |
| NCT00723827 | Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) | COMPLETED | - | Glioblastoma, Glioma, Astrocytoma | Temozolomide, Radiotherapy | - | 2015-01-30 | CT.gov |
| NCT00689221 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status | COMPLETED | PHASE3 | Glioblastoma | Cilengitide, Temozolomide, Radiotherapy | Germany, United States | 2014-11-04 | CT.gov |
| NCT00576641 | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | COMPLETED | PHASE1 | Brain Stem Glioma, Glioblastoma | autologous dendritic cells | United States | 2014-10-30 | CT.gov |
| NCT00362921 | Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Recurrent Adult Brain Tumor | Gliadel wafers in combination with O6-benzylguanine | United States | 2014-07-10 | CT.gov |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | COMPLETED | PHASE1, PHASE2 | Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma +4 | lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study +2 | United States | 2014-05-23 | CT.gov |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | vorinostat, conventional surgery | United States | 2014-05-23 | CT.gov |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | COMPLETED | PHASE2 | Glioblastoma, Gliosarcoma | Avastin, Bortezomib | United States | 2014-03-12 | CT.gov |
| NCT00875433 | Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours | COMPLETED | PHASE2 | Neoplasms | BIBW 2992 | United Kingdom | 2013-12-30 | CT.gov |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | COMPLETED | PHASE2 | Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent | Temozolomide | Turkey (Türkiye) | 2013-12-20 | CT.gov |
| NCT00003185 | Biological Therapy in Treating Patients With Glioblastoma Multiforme | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | autologous tumor cell vaccine, sargramostim, tumor-draining lymph node lymphocyte therapy, cyclophosphamide +1 | United States | 2013-12-04 | CT.gov |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | cediranib maleate | United States | 2013-08-22 | CT.gov |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | COMPLETED | PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide | United States | 2013-08-02 | CT.gov |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | COMPLETED | PHASE1, PHASE2 | Brain Tumor, Glioblastoma | Vorinostst/Bevacizumab/Temozolomide | United States | 2013-06-24 | CT.gov |
| NCT01089868 | Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients | COMPLETED | - | Glioblastoma Multiforme | - | Germany | 2012-08-07 | CT.gov |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP) | COMPLETED | PHASE1, PHASE2 | High-grade Glioma, Astrocytoma, Glioblastoma | 18F Fluorothymidine PET CT | France | 2012-05-04 | CT.gov |
| NCT00004073 | Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | suramin, radiation therapy | United States | 2012-05-03 | CT.gov |
| NCT00003409 | Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1 | Brain and Central Nervous System Tumors | motexafin gadolinium, radiation therapy | United States | 2009-02-09 | CT.gov |
| NCT00001148 | Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor | COMPLETED | - | Astrocytoma, Glioblastoma, Glioma | - | United States | 2008-03-04 | CT.gov |
| NCT00430911 | Radiotherapy for Malignant Astrocytomas in the Elderly | COMPLETED | PHASE3 | Primary Brain Tumor, Anaplastic Astrocytoma, Glioblastoma Multiforme | Radiotherapy | France | 2007-02-02 | CT.gov |
Stopped or withdrawn trials (86)
These rows can provide caution or historical context.
| NCT ID | Title | Status | Phase | Conditions | Interventions | Countries | Last updated | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | TERMINATED | PHASE1 | Glioblastoma, Recurrent Glioblastoma | RMC-5552 | United States | 2026-05-06 | CT.gov |
| NCT05753007 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | TERMINATED | PHASE2 | Glioblastoma | Cannabidiol (CBD), Placebo | United States | 2026-03-16 | CT.gov |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | TERMINATED | PHASE2 | Glioblastoma, Adult-type Diffuse Gliomas | Pemigatinib | Denmark, France, Germany, Italy +5 | 2025-12-30 | CT.gov |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | TERMINATED | PHASE1 | Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme | 68Ga-FF58, 177Lu-FF58 | Israel, Netherlands, Spain, Switzerland | 2025-12-24 | CT.gov |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | TERMINATED | PHASE2 | Glioblastoma, IDH-wildtype | Ropidoxuridine | United States | 2025-12-18 | CT.gov |
| NCT05183204 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | SUSPENDED | PHASE2 | Glioblastoma | Paxalisib, Metformin, Ketogenic Diet | United States | 2025-12-18 | CT.gov |
| NCT06806228 | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) | SUSPENDED | PHASE1 | Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Gliosarcoma, Giant Cell Glioblastoma +1 | S-Gboxin | Georgia, Kazakhstan, Ukraine | 2025-11-19 | CT.gov |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | TERMINATED | PHASE1 | Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma | Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy | United States | 2025-11-13 | CT.gov |
| NCT04657146 | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma | SUSPENDED | - | Glioblastoma | Biorepository | United States | 2025-11-12 | CT.gov |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma | TERMINATED | PHASE2 | Glioblastoma, Surgery, High Grade Glioma | Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide) | United States | 2025-11-10 | CT.gov |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | TERMINATED | EARLY_PHASE1 | Glioma, Glioblastoma, GBM | Infigratinib | United States | 2025-10-24 | CT.gov |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | TERMINATED | PHASE2 | Glioma, Glioblastoma | Soliramfetol | United States | 2025-10-21 | CT.gov |
| NCT04963413 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | TERMINATED | PHASE1 | Glioblastoma | Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF | United States | 2025-08-06 | CT.gov |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | WITHDRAWN | PHASE1 | Recurrent Glioblastoma, Recurrent High-grade Glioma | Bicalutamide, Intensity-modulated radiation therapy (IMRT) | United States | 2025-07-22 | CT.gov |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | TERMINATED | PHASE2 | Glioblastoma, Recurrent Glioblastoma | VB11, Surgery, Placebo, Bevacizumab | United States | 2025-06-10 | CT.gov |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | TERMINATED | PHASE1 | Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma | Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide | United States | 2025-05-07 | CT.gov |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | SUSPENDED | PHASE1 | Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme +3 | Laparoscopically harvested omental free flap | United States | 2025-04-09 | CT.gov |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | WITHDRAWN | PHASE1, PHASE2 | GBM | Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields) | - | 2024-12-04 | CT.gov |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | WITHDRAWN | PHASE2 | Recurrent Glioblastoma | Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab | United States | 2024-11-20 | CT.gov |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | TERMINATED | PHASE1 | Healthy Subject, Intracranial Neoplasm, Glioblastoma | Fluorine F 18 DASA-23, Positron Emission Tomography | United States | 2024-08-12 | CT.gov |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | TERMINATED | PHASE1, PHASE2 | Recurrent GBM | SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS) | United States | 2024-07-26 | CT.gov |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | TERMINATED | PHASE1 | Astrocytoma, Glioblastoma | CC-90010 | Spain, United States | 2024-07-05 | CT.gov |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | TERMINATED | EARLY_PHASE1 | Glioblastoma | 18F-FluorThanatrace | United States | 2024-06-17 | CT.gov |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | TERMINATED | PHASE1, PHASE2 | Recurrent Glioblastoma Multiforme | Berubicin Hydrochloride | Poland | 2024-06-06 | CT.gov |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | SUSPENDED | PHASE3 | Glioblastoma Multiforme | ICT-107, Placebo | Austria, Canada, United States | 2024-04-03 | CT.gov |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | TERMINATED | PHASE1 | Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor | Tumor Treating Fields, Temozolomide, Radiation Therapy | United States | 2024-03-04 | CT.gov |
| NCT04218019 | Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation | WITHDRAWN | NA | Newly Diagnosed Glioblastoma in Patients ≥70 Years | TTFields | Germany | 2024-01-05 | CT.gov |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | WITHDRAWN | PHASE2 | Glioblastoma | ONC201 | United States | 2023-11-24 | CT.gov |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | TERMINATED | PHASE1 | Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors +20 | NUV-422 | United States | 2023-07-14 | CT.gov |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | TERMINATED | PHASE1 | Glioblastoma Multiforme, Anaplastic Astrocytoma | PAC-1 Compound | United States | 2023-05-24 | CT.gov |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | TERMINATED | PHASE1, PHASE2 | Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma +2 | AXL1717 | United States | 2023-05-22 | CT.gov |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | TERMINATED | PHASE1 | Glioblastoma, Glioblastoma, Adult | DNX-2440 injection | Spain | 2023-04-07 | CT.gov |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma | TERMINATED | PHASE1 | Grade IV Astrocytoma, Glioblastoma | Temozolomide, folinic acid at pharmacological dose is the escalated drug, High voltage radiation therapy (linear accelerator) | France | 2023-02-21 | CT.gov |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma | TERMINATED | PHASE1 | Glioblastoma, Gliosarcoma | EGFRvIII CAR T cells | United States | 2023-02-17 | CT.gov |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | WITHDRAWN | PHASE1 | Glioblastoma, Brain Tumor | Temozolomide, Tamoxifen, Maprotiline | - | 2022-08-22 | CT.gov |
| NCT03022578 | Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | TERMINATED | PHASE2 | IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma | Laser Interstitial Thermal Therapy, Lomustine | United States | 2022-08-10 | CT.gov |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens | TERMINATED | PHASE1 | Glioblastoma, Glioblastoma Multiforme | 5-day TMZ, 21-day TMZ, PEP-CMV: Component A, Tetanus-Diphtheria booster +2 | United States | 2022-06-09 | CT.gov |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | WITHDRAWN | PHASE1, PHASE2 | Newly Diagnosed Glioblastoma | GX-I7, Placebo | South Korea | 2022-03-17 | CT.gov |
| NCT01925573 | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | TERMINATED | NA | RECURRENT GLIOBLASTOMA, Brain Tumor | Optune(NOVOTTF-100A) | United States | 2022-02-03 | CT.gov |
| NCT03235934 | Glycemic Impact on Glioblastoma Outcomes | WITHDRAWN | - | Glioblastoma Multiforme, Hyperglycemia | - | Canada | 2021-10-25 | CT.gov |
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | WITHDRAWN | PHASE2 | Glioblastoma | TMS | - | 2021-09-20 | CT.gov |
| NCT02765165 | Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) | TERMINATED | PHASE1, PHASE2 | Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2) | USL311, USL311, USL311, Lomustine | Spain, United States | 2021-07-23 | CT.gov |
| NCT01433991 | A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | TERMINATED | PHASE1, PHASE2 | Advanced Solid Tumors | Golvatinib, Lenvatinib, Lenvatinib | United States | 2021-06-08 | CT.gov |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | TERMINATED | PHASE2 | Glioblastoma, Glioma, Gliosarcoma | Bevacizumab, TTFields Therapy | United States | 2021-06-02 | CT.gov |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | WITHDRAWN | PHASE1 | Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma | Akt/ERK Inhibitor ONC201, Radiation Therapy, Resection | United States | 2021-05-12 | CT.gov |
| NCT02433392 | Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme. | TERMINATED | PHASE1 | Glioma | CM-BC2 | United Kingdom | 2021-04-21 | CT.gov |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | TERMINATED | PHASE1 | Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma +15 | palbociclib isethionate, pharmacological study, laboratory biomarker analysis | United States | 2021-03-02 | CT.gov |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | WITHDRAWN | PHASE1 | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer | NKG2D-based CAR T-cells | China | 2020-10-22 | CT.gov |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma +4 | Rovalpituzumab tesirine, Dexamethasone | United States | 2020-10-19 | CT.gov |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | TERMINATED | PHASE1, PHASE2 | Renal Cell Carcinoma, Neuroendocrine Tumours | 18F-FAZA PET Imaging | Canada | 2019-08-26 | CT.gov |
| NCT00243022 | Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme | TERMINATED | PHASE2 | Brain and Central Nervous System Tumors, Cerebral Edema | Boswellia serrata extract, cyanocobalamin | United States | 2019-04-30 | CT.gov |
| NCT03403803 | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | TERMINATED | - | Glioblastoma | Optune | United States | 2019-03-27 | CT.gov |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | WITHDRAWN | - | Malignant Glioma of Brain, Glioblastoma | Palliative regimen consisting of LITT | United States | 2019-02-27 | CT.gov |
| NCT03293888 | Spectral Analysis Probe to Identify Glioblastoma Cells | TERMINATED | - | Glioblastoma | - | United States | 2019-01-25 | CT.gov |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | TERMINATED | PHASE1 | Glioblastoma, Gliosarcoma | Temozolomide, Radiation, Sorafenib | United States | 2018-11-09 | CT.gov |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | WITHDRAWN | NA | High Grade Malignant Neoplasm, Glioblastoma Multiforme, Anaplastic Astrocytoma | fluorescein, intraoperative MRI | United States | 2018-07-20 | CT.gov |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | WITHDRAWN | PHASE1 | Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas | Axitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MG | Hong Kong, Singapore | 2018-07-19 | CT.gov |
| NCT01870726 | Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma | TERMINATED | PHASE1, PHASE2 | c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | INC280, Buparlisib | Germany, Netherlands, Spain, Switzerland +1 | 2018-05-30 | CT.gov |
| NCT01702792 | Derivation of Tumor Specific Hybridomas | TERMINATED | PHASE1 | Glioblastoma | Tumor Vaccine | - | 2018-04-04 | CT.gov |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | WITHDRAWN | PHASE2 | Glioblastoma | Cilengitide, Bevacizumab, Questionnaire | - | 2018-01-19 | CT.gov |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | TERMINATED | PHASE1 | High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO) +1 | Plerixafor, Plerixafor, Bevacizumab, Plerixafor +1 | United States | 2017-11-17 | CT.gov |
| NCT02039778 | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | TERMINATED | NA | Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma | Stem Cell Radiotherapy (ScRT) and Temozolomide | United States | 2017-06-05 | CT.gov |
| NCT02129335 | Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner | TERMINATED | - | Neoplasms, Glioblastoma | stress | Switzerland | 2017-05-17 | CT.gov |
| NCT00436436 | O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy | TERMINATED | PHASE2 | Brain and Central Nervous System Tumors | O6-benzylguanine, temozolomide | United States | 2017-03-28 | CT.gov |
| NCT02394665 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | TERMINATED | PHASE2 | Glioblastoma | Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost +2 | United States | 2017-01-05 | CT.gov |
| NCT02841332 | Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma | TERMINATED | NA | Glioblastoma | F-MISO, Cerebral magnetic resonance imagery, Bevacizumab, Clinical examination | France | 2016-12-20 | CT.gov |
| NCT00473408 | The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas | TERMINATED | - | Anaplastic Astrocytoma, Glioblastoma Multiforme, Tumor Angiogenesis | Functional MRI (DCE-MRI), Blood sample, Tumor sample | Norway | 2016-12-06 | CT.gov |
| NCT01113463 | TPI 287 in Patients With Recurrent Glioblastoma Multiforme | TERMINATED | PHASE2 | Brain Cancer | TPI 287 | United States | 2016-10-31 | CT.gov |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | WITHDRAWN | PHASE2 | Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant +11 | 5-ALA (Gliolan) | United States | 2016-05-17 | CT.gov |
| NCT01499251 | Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma | TERMINATED | PHASE1 | Glioblastoma | Phase 1 Dose Escalation, Phase 1b, Ancillary Study | United States | 2016-05-05 | CT.gov |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | TERMINATED | PHASE2 | Glioblastoma Multiforme | TRC105 | United States | 2015-10-07 | CT.gov |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | TERMINATED | PHASE1 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm +1 | Cilengitide, Clinical Observation, Laboratory Biomarker Analysis | United States | 2015-04-28 | CT.gov |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | TERMINATED | PHASE1 | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma +3 | Vorinostat, Stereotactic Radiosurgery, Laboratory Biomarker Analysis, Pharmacological Study +1 | United States | 2014-12-23 | CT.gov |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | TERMINATED | PHASE3 | Anaplastic Astrocytoma, Glioblastoma | trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System +2 | Argentina, Austria, Brazil, Canada +12 | 2014-11-14 | CT.gov |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens | WITHDRAWN | PHASE1 | Glioblastoma | PEP-CMV, PEP-CMV, PEP-CMV | - | 2014-01-14 | CT.gov |
| NCT01011231 | Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma | TERMINATED | PHASE2 | Glioblastoma | Gamma Knife Radiosurgery | United States | 2013-05-06 | CT.gov |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | TERMINATED | PHASE1, PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | oxaliplatin, pharmacological study | United States | 2013-01-24 | CT.gov |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) | WITHDRAWN | PHASE2 | Glioblastoma Multiforme | IL-4PE | - | 2012-12-03 | CT.gov |
| NCT01044225 | Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma | TERMINATED | PHASE2 | Glioblastoma | Cetuximab, Cilengitide EMD 121974 | Belgium | 2012-03-22 | CT.gov |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | WITHDRAWN | PHASE1 | Glioblastoma | SCH 900105 | - | 2012-02-20 | CT.gov |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | TERMINATED | PHASE1 | Glioblastoma Multiforme | Temodar (Temozolomide), Hominex-2 | United States | 2012-01-16 | CT.gov |
| NCT01105988 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | TERMINATED | EARLY_PHASE1 | Glioblastoma | Radiologic exams | United States | 2012-01-06 | CT.gov |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | TERMINATED | PHASE2 | Recurrent Glioblastoma Multiforme (GBM) | Imatinib tablets, Hydroxyurea capsules | United States | 2011-05-16 | CT.gov |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | TERMINATED | PHASE1, PHASE2 | Glioblastoma Multiforme | temozolomide, Brachytherapy, External Beam Radiation Therapy | United States | 2009-09-18 | CT.gov |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | TERMINATED | PHASE2 | Glioblastoma, Gliosarcoma | Temozolomide | United States | 2009-01-22 | CT.gov |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | WITHDRAWN | PHASE3 | Glioblastoma Multiforme | TransMID™ | Australia, United States | 2009-01-07 | CT.gov |
Show other historical trials (88)
Other historical trials (88)
Open identifiers on the public registry for primary protocol text.
| NCT ID | Title | Status | Phase | Conditions | Interventions | Countries | Last updated | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04998864 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients | COMPLETED | - | Glioma, Malignant, Glioblastoma | Magnetic Resonance guided Focused ultrasound (MRgFUS) | Italy, Spain | 2026-04-16 | CT.gov |
| NCT04730869 | Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma | COMPLETED | NA | Glioblastoma | Standard Treatment Plus Metabolic Therapy Program | New Zealand | 2026-04-09 | CT.gov |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1, PHASE2 | Glioblastoma | Dendritic Cells Vaccine | Italy | 2026-03-27 | CT.gov |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | COMPLETED | PHASE1 | Glioblastoma Multiforme (GBM) | Hyperpolarized 13C Pyruvate | United States | 2026-03-27 | CT.gov |
| NCT06665724 | Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401) | COMPLETED | PHASE1 | Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM) | 5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01 | Germany | 2026-02-27 | CT.gov |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | COMPLETED | PHASE1, PHASE2 | Recurrent Glioblastoma | Exablate BBBD, Carboplatin | Canada, Italy, South Korea | 2026-01-20 | CT.gov |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | COMPLETED | PHASE1 | Glioblastoma, Newly Diagnosed Glioblastoma | Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS) | United States | 2025-12-26 | CT.gov |
| NCT05190315 | Chlorpromazine and Standard of Care in Glioblastoma | COMPLETED | PHASE1 | Glioblastoma Multiforme | Chlorpromazine, Temozolomide, Radiation Therapy | United States | 2025-09-02 | CT.gov |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | COMPLETED | PHASE1, PHASE2 | Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1 | VAL-083 (Dianhydrogalactitol) | United States | 2025-08-29 | CT.gov |
| NCT02717962 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | COMPLETED | PHASE2 | Glioma, Glioblastoma, Glioblastoma Multiforme, GBM +1 | VAL-083, Dianhydrogalactitol | United States | 2025-08-29 | CT.gov |
| NCT07120620 | PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma | COMPLETED | PHASE1, PHASE2 | Glioblastoma Multiforme (GBM) | TTFields before and during radiotherapy, TTFields before and during radiotherapy | Germany | 2025-08-13 | CT.gov |
| NCT04051606 | Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | COMPLETED | PHASE2 | Recurrent Glioblastoma | Regorafenib | United States | 2025-06-05 | CT.gov |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | COMPLETED | NA | Cancer, Cancer Metastatic, Neoplasms, Breast Cancer +18 | Virtual group based physical activity (BurnAlong) and Social Media Discussion Board | United States | 2025-02-26 | CT.gov |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | COMPLETED | PHASE1 | Glioblastoma, Recurrent Glioblastoma | Adavosertib, Radiation Therapy, Temozolomide | United States | 2025-01-09 | CT.gov |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | UCPVax, Temozolomide | France | 2025-01-09 | CT.gov |
| NCT05015543 | Physical Training in Glioblastoma Patients During Cytotoxic Therapy | COMPLETED | NA | Glioblastoma | Personal Training Program | Germany | 2024-12-12 | CT.gov |
| NCT03865355 | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients | COMPLETED | - | Glioma, Glioblastoma Multiforme | Non- interventional | Russia | 2024-11-14 | CT.gov |
| NCT03922984 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | COMPLETED | NA | Glioblastoma | MRI with Arterial Spin Labeling (ASL) | United States | 2024-10-22 | CT.gov |
| NCT06600399 | Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma | COMPLETED | - | Glioblastoma | glioblastoma | China | 2024-09-19 | CT.gov |
| NCT05977738 | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin | COMPLETED | EARLY_PHASE1 | Glioblastoma Multiforme, Adult, Recurrent Glioblastoma | Pitavastatin calcium | Netherlands | 2024-08-07 | CT.gov |
| NCT06038604 | Glioblastoma Psychosocial Support Program | COMPLETED | NA | Glioblastoma | Psychosocial Support Intervention | United States | 2024-07-31 | CT.gov |
| NCT06346821 | Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data | COMPLETED | - | Glioblastoma Multiforme | Optune® (Tumor Treating Fields) | China | 2024-07-03 | CT.gov |
| NCT05402241 | IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study | COMPLETED | - | Glioblastoma Multiforme | - | Canada | 2024-05-23 | CT.gov |
| NCT03454295 | Easing Psychosocial Burden for Informal Caregivers | COMPLETED | EARLY_PHASE1 | Glioblastoma | Focus Group, Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C, Enhanced Usual Care / EUC | United States | 2024-04-01 | CT.gov |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma | COMPLETED | PHASE1, PHASE2 | Glioblastoma | PF-04449913, Temozolomide Oral Capsule | Spain | 2024-03-28 | CT.gov |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | COMPLETED | - | Glioblastoma | Blood drawl | Austria, Belgium, France, Germany +5 | 2024-03-08 | CT.gov |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | COMPLETED | PHASE1 | Glioblastoma | TH-1 Dendritic Cell Immunotherapy | United States | 2024-01-11 | CT.gov |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | COMPLETED | PHASE1 | Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm | Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis +1 | United States | 2023-10-06 | CT.gov |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | COMPLETED | PHASE1, PHASE2 | Glioblastoma | Drug is Anlotinib., Drug is Temozolomide Capsule., Radiotherapy was initiated 4 to 6 weeks postoperatively. | China | 2023-09-22 | CT.gov |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | COMPLETED | PHASE2 | Glioblastoma | Temozolomide | - | 2023-07-24 | CT.gov |
| NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | COMPLETED | PHASE1 | Glioblastoma | CART-EGFRvIII T cells, Pembrolizumab | United States | 2023-06-22 | CT.gov |
| NCT00584883 | A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1 | Brain Tumor | ABT 510 | United States | 2023-06-07 | CT.gov |
| NCT03618667 | GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification | COMPLETED | PHASE2 | Glioblastoma, Adult, EGFR Amplification | GC1118 | South Korea | 2023-05-12 | CT.gov |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | COMPLETED | PHASE1 | Glioma, Malignant, Gliosarcoma, Astrocytoma of Brain | Intranasal Modified Temozolomide | Bosnia and Herzegovina, Bulgaria, Georgia | 2023-04-25 | CT.gov |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | COMPLETED | PHASE1 | Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma +6 | Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus | United States | 2023-04-24 | CT.gov |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | COMPLETED | PHASE1, PHASE2 | Non-small Cell Lung Cancer, Glioblastoma Multiforme | GLR2007 | United States | 2022-12-23 | CT.gov |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) | COMPLETED | PHASE3 | Glioblastoma, Adult | Fluorescéine Sodique Faure, White-light surgery | France | 2022-11-09 | CT.gov |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | COMPLETED | EARLY_PHASE1 | Brain Glioblastoma | Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography | United States | 2022-07-21 | CT.gov |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | COMPLETED | PHASE1 | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma | Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis | United States | 2022-07-20 | CT.gov |
| NCT03877861 | Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms | COMPLETED | - | Glioma, Glioblastoma | Readiband Sleep Tracking | United States | 2021-06-09 | CT.gov |
| NCT04846257 | Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence | COMPLETED | - | Glioblastoma | Dynamic contrast-enhanced MRI | Egypt | 2021-04-19 | CT.gov |
| NCT03033524 | Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma | COMPLETED | PHASE2 | Recurrent Glioblastoma | TTAC-0001 | - | 2021-01-27 | CT.gov |
| NCT01905228 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | COMPLETED | PHASE1 | Solid Tumors, Glioblastoma | CBL0137 | United States | 2020-12-10 | CT.gov |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | COMPLETED | PHASE1, PHASE2 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | gefitinib, radiation therapy, laboratory biomarker analysis | United States | 2020-10-30 | CT.gov |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | COMPLETED | PHASE1 | Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma +16 | CC-486, Vidaza | United States | 2020-05-12 | CT.gov |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | ALECSAT, Radiotherapy, Temozolomide | Sweden | 2020-04-30 | CT.gov |
| NCT00009035 | Natural History of Patients With Brain and Spinal Cord Tumors | COMPLETED | - | Astrocytoma, Oligodendroglioma, Glioblastoma, Glioma +1 | - | United States | 2019-12-12 | CT.gov |
| NCT02364206 | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma | COMPLETED | PHASE1, PHASE2 | Adult Glioblastoma | LY2228820, Temozolomide, radiotherapy | France | 2019-08-14 | CT.gov |
| NCT02575027 | Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme | COMPLETED | NA | Glioblastoma, Recurrent Brain Neoplasm | Palliative Radiation Therapy, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation | United States | 2019-02-28 | CT.gov |
| NCT01873469 | Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme | COMPLETED | - | Glioblastoma Multiforme | Radiochemotherapy | Germany | 2019-02-18 | CT.gov |
| NCT00006452 | Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme | COMPLETED | PHASE1 | Brain and Central Nervous System Tumors | motexafin gadolinium, radiation therapy | - | 2018-06-27 | CT.gov |
| NCT02466828 | qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | COMPLETED | EARLY_PHASE1 | Glioblastoma, Hypoxia | Feraheme® | Canada | 2018-04-18 | CT.gov |
| NCT02507102 | A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia | COMPLETED | NA | Glioblastoma Multiforme | Voyager | Australia | 2018-03-30 | CT.gov |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | Bevacizumab, Onartuzumab, Placebo | Canada, France, Germany, Italy +4 | 2018-02-05 | CT.gov |
| NCT00897663 | Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies | COMPLETED | - | Brain and Central Nervous System Tumors | gene expression analysis, microarray analysis, protein expression analysis, diagnostic laboratory biomarker analysis +1 | United States | 2018-01-24 | CT.gov |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | temozolomide and bevacizumab | United States | 2017-03-30 | CT.gov |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | COMPLETED | PHASE1 | Glioblastoma Multiforme | RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin] | Denmark, France, Switzerland, United Kingdom | 2016-11-02 | CT.gov |
| NCT01588769 | A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | COMPLETED | PHASE1 | Glioblastoma Multiforme | ALECSAT cell based immunotherapy | Denmark | 2016-06-06 | CT.gov |
| NCT01833273 | Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA | COMPLETED | PHASE1 | Glioblastoma Multiform (Grade IV Astrocytoma) | PolyMVA | United States | 2016-06-03 | CT.gov |
| NCT01222221 | Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1 | Brain and Central Nervous System Tumors | glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide, laboratory biomarker analysis +3 | United Kingdom | 2015-10-14 | CT.gov |
| NCT01102595 | Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma | COMPLETED | PHASE2 | Glioblastomas | Temozolomide, Bevacizumab, Standard radiation therapy | Spain | 2015-08-26 | CT.gov |
| NCT00979862 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | COMPLETED | PHASE1 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm | Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis | United States | 2015-04-15 | CT.gov |
| NCT00049387 | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | COMPLETED | PHASE1 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | tipifarnib, temozolomide, radiation therapy | United States | 2015-04-15 | CT.gov |
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | COMPLETED | PHASE1, PHASE2 | Brain Tumor, Recurring Glioblastoma | delta-24-RGD adenovirus | Netherlands | 2015-03-09 | CT.gov |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | COMPLETED | PHASE1, PHASE2 | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma | IL13-PE38QQR, targeted fusion protein therapy, surgery | United States | 2014-11-14 | CT.gov |
| NCT00609999 | Ph I Dasatinib + Erlotinib in Recurrent MG | COMPLETED | PHASE1 | Glioblastoma, Gliosarcoma | Erlotinib and Dasatinib | United States | 2014-07-16 | CT.gov |
| NCT00612989 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | COMPLETED | PHASE1 | Glioblastoma, Gliosarcoma | Temodar and O6-Benzylguanine | United States | 2014-07-16 | CT.gov |
| NCT00677716 | Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse | COMPLETED | PHASE2 | Glioblastoma Multiforme | 131I-chTNT-1/B MAb (Cotara) | India, United States | 2014-04-24 | CT.gov |
| NCT00919737 | Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | COMPLETED | PHASE1, PHASE2 | Malignant Glioma | NPC-08 | Japan | 2013-10-30 | CT.gov |
| NCT00039572 | Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain | COMPLETED | PHASE1, PHASE2 | Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer | boronophenylalanine-fructose complex | United States | 2013-06-26 | CT.gov |
| NCT00780819 | Borderzone Sampling | COMPLETED | NA | High Grade Glioma, Glioblastoma | PoleStar N20 intraoperative MRI | Netherlands | 2013-05-14 | CT.gov |
| NCT00704080 | A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas | COMPLETED | PHASE1 | Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme | XL765 (SAR245409), Temozolomide | United States | 2013-04-10 | CT.gov |
| NCT00316849 | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy +2 | United States | 2013-04-10 | CT.gov |
| NCT00045565 | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | COMPLETED | PHASE1 | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma | arsenic trioxide, radiation therapy | United States | 2013-04-09 | CT.gov |
| NCT01100177 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | COMPLETED | PHASE2 | Glioblastoma | Sunitinib, Radiation | Spain | 2013-03-11 | CT.gov |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | COMPLETED | PHASE1 | Gliosarcoma, Glioblastoma | Vandetanib and Etoposide | United States | 2013-02-20 | CT.gov |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | COMPLETED | PHASE2 | Glioblastoma | CpG-ODN | France | 2012-12-13 | CT.gov |
| NCT00753246 | Nimotuzumab in Adults With Glioblastoma Multiforma | COMPLETED | PHASE3 | Adults With Glioblastoma Multiforma | nimotuzumab | Germany | 2012-12-03 | CT.gov |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | COMPLETED | PHASE2 | Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma | LS11 (talaporfin sodium), Light source (interstitial light emitting diodes), Intraoperative placement of device in glioma | Serbia | 2012-11-16 | CT.gov |
| NCT00002619 | Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | filgrastim, carboplatin, thiotepa, autologous bone marrow transplantation +1 | United States | 2012-11-09 | CT.gov |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | COMPLETED | PHASE2 | Recurrent Glioblastoma Multiforme | TP-38, TP38 | - | 2012-01-20 | CT.gov |
| NCT00209989 | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | COMPLETED | PHASE2 | Glioblastoma Multiforme | Zarnestra, standard Radiation therapy | France | 2011-11-24 | CT.gov |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | COMPLETED | PHASE2 | Glioblastoma Multiforme | TP-38 | - | 2011-05-23 | CT.gov |
| NCT00010036 | Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | COMPLETED | PHASE2 | Brain and Central Nervous System Tumors | carboplatin, irinotecan hydrochloride, radiation therapy | United States | 2011-03-28 | CT.gov |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | COMPLETED | PHASE2 | Glioblastoma Multiforme | Temsirolimus, Bevacizumab | Denmark | 2010-06-02 | CT.gov |
| NCT00053183 | Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | COMPLETED | PHASE1 | Brain and Central Nervous System Tumors | conventional surgery, brachytherapy, radiation therapy | United States | 2009-02-09 | CT.gov |
| NCT00032097 | Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain | COMPLETED | PHASE1 | Brain and Central Nervous System Tumors | motexafin gadolinium, radiation therapy | United States | 2009-02-09 | CT.gov |
| NCT00463073 | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | COMPLETED | PHASE2 | Malignant Gliomas | Cetuximab, Bevacizumab, Irinotecan | Denmark | 2008-12-11 | CT.gov |
Show other historical trials (41)
Other historical trials (41)
Open identifiers on the public registry for primary protocol text.
| NCT ID | Title | Status | Phase | Conditions | Interventions | Countries | Last updated | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05551013 | Treatment of Recurrent GBM With APG-157 Via Expanded Access | NO_LONGER_AVAILABLE | - | Glioblastoma, Glioblastoma Multiforme | APG-157 | - | 2024-08-09 | CT.gov |
| NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) | UNKNOWN | PHASE2 | Newly Diagnosed Glioblastoma | TJ107, TJ107 placebo | China, Hong Kong | 2024-04-15 | CT.gov |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression | UNKNOWN | PHASE1, PHASE2 | Glioblastoma | L19TNF, Lomustine | France, Germany, Italy, Switzerland | 2024-04-08 | CT.gov |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma | UNKNOWN | PHASE1, PHASE2 | Glioblastoma Multiforme of Brain | Cisplatin Plus Temozolomide, Temozolomide | - | 2024-01-02 | CT.gov |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine | UNKNOWN | PHASE2 | Glioblastoma Multiforme, Recurrent Glioblastoma | TTFields and SRS | Poland | 2023-06-28 | CT.gov |
| NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | UNKNOWN | PHASE2 | Recurrent Glioblastoma | GX-I7, Bevacizumab | South Korea | 2023-06-12 | CT.gov |
| NCT05694416 | Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | UNKNOWN | PHASE2 | MGMT-Unmethylated Glioblastoma | Etoposide Plus Cisplatin | - | 2023-01-23 | CT.gov |
| NCT05512195 | Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma | UNKNOWN | NA | Glioblastoma | New delineation approach | - | 2022-08-23 | CT.gov |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma | UNKNOWN | NA | Glioma Glioblastoma Multiforme | Standard of Care, Additional pre- and intra-operative imaging | United Kingdom | 2022-06-01 | CT.gov |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer | UNKNOWN | PHASE3 | Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma +3 | Dendritic cell immunotherapy | Canada, Germany, United Kingdom, United States | 2022-05-18 | CT.gov |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | UNKNOWN | EARLY_PHASE1 | Glioblastoma Multiforme, Adult | Tumor Infiltrating Lymphocytes (TIL) | China | 2022-04-19 | CT.gov |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | UNKNOWN | PHASE1 | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer | NKG2D-based CAR T-cells | China | 2021-11-23 | CT.gov |
| NCT05053880 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | UNKNOWN | PHASE1, PHASE2 | Recurrent Glioblastoma Multiforme(GBM) | ACT001, ACT001 + Pembrolizumab | United States | 2021-11-19 | CT.gov |
| NCT04970615 | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models | UNKNOWN | - | Brain Tumor, Glioma, Glioblastoma, Astrocytoma +4 | Three-dimensional printed model | Netherlands | 2021-07-21 | CT.gov |
| NCT04902586 | Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma | UNKNOWN | NA | Glioma, Glioblastoma | TTFields | China | 2021-05-26 | CT.gov |
| NCT04180046 | Utility of Primary Glioblastoma Cell Lines | UNKNOWN | - | Tumor, Brain Tumor | - | Italy | 2021-04-12 | CT.gov |
| NCT04772846 | Chloroquine for Glioblastoma. | UNKNOWN | PHASE1, PHASE2 | Glioblastoma | Oral tablet, Placebo | Egypt | 2021-02-26 | CT.gov |
| NCT04547621 | HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM | UNKNOWN | PHASE1, PHASE2 | Glioma, Malignant | Radiation, Radiation, Temozolomide | China | 2020-09-14 | CT.gov |
| NCT04547855 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | UNKNOWN | PHASE2 | Glioblastoma | anlotinib combined with dose-dense temozolomide | China | 2020-09-14 | CT.gov |
| NCT04536649 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | UNKNOWN | PHASE3 | Glioblastoma | Radiotherapy | China | 2020-09-02 | CT.gov |
| NCT03914768 | Immune Modulatory DC Vaccine Against Brain Tumor | UNKNOWN | PHASE1 | Diffuse Intrinsic Pontine Glioma or Glioblastoma | Immunomodulatory DC vaccine to target DIPG and GBM | China | 2020-06-12 | CT.gov |
| NCT03567135 | Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma | UNKNOWN | - | Glioblastoma | Apatinib, Temozolomide(TMZ) | China | 2020-03-03 | CT.gov |
| NCT03409549 | Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma | UNKNOWN | - | Tumor, Brain | Fluciclovine PET/CT | United Kingdom | 2019-08-06 | CT.gov |
| NCT02520635 | Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients | UNKNOWN | - | Glioblastoma | supra-early TEMODAL® chemotherapy, standard TEMODAL® chemotherapy, Radiotherapy 60Gy | China | 2019-07-11 | CT.gov |
| NCT03687034 | A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma | UNKNOWN | PHASE1 | Glioblastoma | Temozolomide, Optune | - | 2019-02-26 | CT.gov |
| NCT03642080 | MRI Predictors of Response to Tumor Treating Fields | UNKNOWN | - | Glioblastoma Multiforme | - | United States | 2018-12-19 | CT.gov |
| NCT03633552 | Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma | UNKNOWN | PHASE3 | Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain | Temozolomide | Iran | 2018-08-16 | CT.gov |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | UNKNOWN | PHASE2 | Glioblastoma Multiforme | One injection of 68Ga-NOTA-AE105, PET/MRI | Denmark | 2018-04-10 | CT.gov |
| NCT03370926 | FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy | UNKNOWN | - | Glioblastoma Multiforme, Anaplastic Astrocytoma, Radiotherapy | - | France | 2017-12-13 | CT.gov |
| NCT02152748 | Disease Progression and Treatment-induced Alterations in Glioblastoma | UNKNOWN | - | Brain Tumor | analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance | Austria | 2017-03-22 | CT.gov |
| NCT02815410 | Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients | UNKNOWN | PHASE2 | Glioblastoma Multiforme | levetiracetam | - | 2016-06-28 | CT.gov |
| NCT01939574 | A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma | UNKNOWN | NA | Glioblastoma | Chemoradiation Therapy, Adjuvant Therapy | China | 2016-01-21 | CT.gov |
| NCT02623231 | The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients | UNKNOWN | PHASE2, PHASE3 | GBM, Depression | Escitalopram, placebo | Israel | 2015-12-07 | CT.gov |
| NCT01637753 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | UNKNOWN | NA | Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma | Carmustine(BCNU), Surgery | China | 2012-07-11 | CT.gov |
| NCT01124240 | Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene | UNKNOWN | PHASE2 | Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 | Cilengitide | Australia | 2011-07-26 | CT.gov |
| NCT01317888 | Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas | UNKNOWN | NA | Glioblastoma Multiforme, Astrocytoma Anaplastic Foci | MAB-425 radiolabeled with I-125 | - | 2011-03-17 | CT.gov |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | UNKNOWN | PHASE2 | Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | CT-322, irinotecan hydrochloride | United States | 2010-10-27 | CT.gov |
| NCT01208909 | Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI) | UNKNOWN | - | Glioblastoma | diagnostic 5-ALA and MRI for tumor resection | Switzerland | 2010-10-22 | CT.gov |
| NCT00906516 | Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme | UNKNOWN | PHASE2 | Brain Tumors | Neuradiab in combination with Bevacizumab (Avastin) | United States | 2009-05-21 | CT.gov |
| NCT00114309 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | UNKNOWN | PHASE2 | Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma +2 | 131-I-TM-601, 131I-TM601 | United States | 2009-04-03 | CT.gov |
| NCT00394628 | AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme | UNKNOWN | PHASE1, PHASE2 | Glioblastoma Multiforme | AQ4N, Temozolomide, Radiotherapy | United States | 2007-05-30 | CT.gov |